A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
- Interventions
- Registration Number
- NCT06119581
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
- Detailed Description
Dose Optimization, Part A, and Part B are randomized. Safety Lead-In for Part B is single arm, non-randomized.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1016
-
Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.
-
Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).
-
Must have disease with evidence of KRAS G12C mutation.
-
Must have known programmed death-ligand 1 (PD-L1) expression
- Part A: Greater than or equal to (≥)50 percent (%).
- Part B: 0% to 100%.
-
Must have measurable disease per RECIST v1.1.
-
Must have an ECOG performance status of 0 or 1.
-
Estimated life expectancy ≥12 weeks.
-
Ability to swallow capsules.
-
Must have adequate laboratory parameters.
-
Contraceptive use should be consistent with local regulations for those participating in clinical studies.
-
Women of childbearing potential must
- Have a negative pregnancy test.
- Not be breastfeeding during treatment
-
Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.
-
Have had any of the following prior to randomization:
-- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.
--- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:
-
Have known active central nervous system metastases and/or carcinomatous meningitis.
Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)
- Have predominantly squamous cell histology for NSCLC
- Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)
- Is unable or unwilling to take folic acid or vitamin B12 supplementation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab Pembrolizumab LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab LY3537982 LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab Pembrolizumab LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Pembrolizumab LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Cisplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Carboplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum Pemetrexed LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: LY3537982 plus Pembrolizumab Pembrolizumab LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: Placebo plus Pembrolizumab Pembrolizumab Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: Placebo plus Pembrolizumab Placebo Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Pembrolizumab LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Cisplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Carboplatin LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum Pemetrexed LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Pembrolizumab Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Placebo Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Cisplatin Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Carboplatin Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum Pemetrexed Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab LY3537982 LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum LY3537982 LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part A: LY3537982 plus Pembrolizumab LY3537982 LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum LY3537982 LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
- Primary Outcome Measures
Name Time Method Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE) Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year) Dose Optimization and Safety Lead-In Part B: Number of Participants with a TEAE
Part A and Part B: Progression-Free Survival (PFS) Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year) PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR)
- Secondary Outcome Measures
Name Time Method Part A and Part B: Overall Survival (OS) Randomization to date of death from any cause. (Estimated as up to 3 years) Part A and Part B: OS
Part A and Part B: Overall Response Rate (ORR): Percentage of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) Randomization to disease progression or death. (Estimated as approximately 1 year) ORR per RECIST v1.1 by BICR
Part A and Part B: Duration of Response (DOR) Date of first evidence of CR or PR to date of disease progression or death from any cause. (Estimated as approximately 1 year) DOR per RECIST v1.1 by BICR
Part A and Part B: Disease Control Rate (DCR): Percentage of Participants who Achieve a BOR of CR, PR, or Stable Disease (SD) Randomization to disease progression or death from any cause. (Estimated as approximately 1 year) DCR per RECIST v1.1 by BICR
Part A and Part B: Time to Response (TTR) Time from randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 1 year) TTR per RECIST v1.1 by BICR
Part A and Part B: Intracranial Overall Response Rate (ORR) Randomization to intracranial disease progression or death. (Estimated as approximately 1 year) Intracranial ORR per RECIST v1.1 by BICR
Part A and Part B: Intracranial Duration of Response (DoR) Date of first evidence of CR or PR to date of intracranial disease progression or death from any cause. (Estimated as approximately 1 year) Intracranial DoR per RECIST v1.1 by BICR
Part A and Part B: PFS2 Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 1 year Part A and Part B: PFS2 by Investigator
Part A and Part B: Changes in NSCLC-related symptoms as measured by NSCLC-SAQ Randomization through end of treatment (Estimated as approximately 1 year)] NSCLC-related symptoms are assessed by the NSCLC-SAQ total score, which is computed as the sum of the 5 domains (7 questions) and ranges from 0 to 20. The total score will be calculated if all 7 questions are completed. Higher scores indicate more severe symptomatology.
Part A and Part B: Time to Worsening of NSCLC-related Symptoms as Measured by NSCLC Symptom Assessment Questionnaire (NSCLC-SAQ) Randomization through end of treatment (Estimated as approximately 1 year) NSCLC symptoms will be assessed using the 7-item NSCLC-SAQ. The NSCLC-SAQ measures overall symptom severity of NSCLC, including cough, pain, dyspnea, fatigue, and poor appetite. Response options range from 0) "Not at all" to 4) "Always" or from 0) "Never" to 4) "Always." The total score ranges from 0-20. Higher scores represent worse symptoms.
Part A and Part B: Changes in physical function, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) Physical Functioning subscale and IL19 Randomization through end of treatment (Estimated as approximately 1 year) Physical function is assessed by EORTC-QLQ-C30 Physical Functioning scale or IL19. The physical function score is calculated by generating the raw score: (Q1+Q2+Q3+Q4+Q5)/5; and then generating the transformed score: (1-((raw score-1)/3)) x 100. The score ranges from 0 to 100. Higher scores indicate better physical function.
Part A and Part B: Time to Deterioration in Physical Function, as Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30) Physical Functioning Subscale and IL19 Randomization through end of treatment (Estimated as approximately 1 year) The EORTC QLQ-C30 is a 30-question patient-reported instrument used to assess multidimensional health-related quality of life (HRQoL) in cancer patients. Physical functioning is measured by the EORTC-QLQ-30 Physical Function Scale (five items). Response options range from 1) "Not at all" to 4) "Very much." The sum score is linearly transformed to the range 0 - 100. Higher scores represent better physical function.
Part A and Part B: Proportion of Time with High Side-Effect Burden, as Measured by Functional Assessment of Cancer Therapy - General Item 5 (FACT-GP5) Randomization through end of treatment (Estimated as approximately 1 year) FACT-GP5 is a single-item, patient-reported instrument for assessing overall treatment side-effect burden. Response options range from 0) "Not at all" to 4) "Very much." Higher scores represent higher symptom burden.
Part A and Part B: Change from Baseline in Overall Health-related Quality of Life, as Measured by the EORTC QLQ-C30 Global Health Status/Quality of Life Subscale Randomization through end of treatment (Estimated as approximately 1 year) The EORTC QLQ-C30 is a 30-question patient-reported instrument used to assess multidimensional HRQoL in cancer patients. Overall HRQoL is measured by the EORTC QLQ-30 Global Health Status/Quality of Life Subscale (two items). Response options range from 1) "very poor" to 7) "excellent." Scores are linearly transformed to the range 0 - 100. Higher scores represent better overall HRQoL.
Trial Locations
- Locations (425)
Clearview Cancer Institute
🇺🇸Huntsville, Alabama, United States
Banner MD Anderson Cancer Center
🇺🇸Gilbert, Arizona, United States
Banner University Medical Center Phoenix
🇺🇸Phoenix, Arizona, United States
The University of Arizona Cancer Center - North Campus
🇺🇸Tucson, Arizona, United States
Highlands Oncology Group
🇺🇸Springdale, Arkansas, United States
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
Mercy Cancer Center
🇺🇸Merced, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
🇺🇸Torrance, California, United States
BASS Cancer Center
🇺🇸Walnut Creek, California, United States
USO - Rocky Mountain Cancer Centers
🇺🇸Lone Tree, Colorado, United States
Yale University School of Medicine
🇺🇸New Haven, Connecticut, United States
Sibley Memorial Hospital
🇺🇸Washington, District of Columbia, United States
Millennium Oncology Research Clinic
🇺🇸Hollywood, Florida, United States
University of Florida - Jacksonville
🇺🇸Jacksonville, Florida, United States
Miami Cancer Institute at Baptist Health, Inc.
🇺🇸Miami, Florida, United States
Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala
🇺🇸Ocala, Florida, United States
Comprehensive Hematology Oncology
🇺🇸Saint Petersburg, Florida, United States
Tampa General Hospital
🇺🇸Tampa, Florida, United States
University Cancer & Blood Center, LLC
🇺🇸Athens, Georgia, United States
Winship Cancer Institute, Emory University
🇺🇸Atlanta, Georgia, United States
University of Illinois at Chicago
🇺🇸Chicago, Illinois, United States
University of Chicago Hospital
🇺🇸Chicago, Illinois, United States
Springfield Clinic Main Campus
🇺🇸Springfield, Illinois, United States
Parkview Research Center at Parkview Regional Medical Center
🇺🇸Fort Wayne, Indiana, United States
Indiana University Melvin and Bren Simon Cancer Center
🇺🇸Indianapolis, Indiana, United States
Franciscan Health
🇺🇸Indianapolis, Indiana, United States
Community Cancer Center North
🇺🇸Indianapolis, Indiana, United States
The University of Kansas Cancer Center - Westwood
🇺🇸Westwood, Kansas, United States
CHI Saint Joseph Cancer Center - East
🇺🇸Lexington, Kentucky, United States
University of Kentucky Chandler Medical Center
🇺🇸Lexington, Kentucky, United States
Mary Bird Perkins Cancer Center
🇺🇸Baton Rouge, Louisiana, United States
USO - Maryland Oncology Hematology
🇺🇸Annapolis, Maryland, United States
Johns Hopkins Bayview Medical Center
🇺🇸Baltimore, Maryland, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
Lahey Hospital & Medical Center
🇺🇸Burlington, Massachusetts, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
The Cancer & Hematology Centers
🇺🇸Grand Rapids, Michigan, United States
Allina Health Cancer Institute - Abbott Northwestern Hospital
🇺🇸Minneapolis, Minnesota, United States
HealthPartners Cancer Research Center
🇺🇸Saint Paul, Minnesota, United States
North Mississippi Hematology and Oncology Associates
🇺🇸Tupelo, Mississippi, United States
Saint Louis University Cancer Center
🇺🇸Saint Louis, Missouri, United States
Oncology Hematology Associates
🇺🇸Springfield, Missouri, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
The Valley Hospital, Inc.
🇺🇸Paramus, New Jersey, United States
University of New Mexico Comprehensive Cancer Center
🇺🇸Albuquerque, New Mexico, United States
Maimonides Cancer Center
🇺🇸Brooklyn, New York, United States
Northwell Health/ RJ Zuckerberg Cancer Center
🇺🇸Lake Success, New York, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
🇺🇸Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center
🇺🇸New York, New York, United States
Manhattan Eye, Ear and Throat Hospital
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Clinical Research Alliance
🇺🇸Westbury, New York, United States
University of North Carolina Medical Center
🇺🇸Chapel Hill, North Carolina, United States
Duke Cancer Institute
🇺🇸Durham, North Carolina, United States
UNC REX Cancer Center
🇺🇸Raleigh, North Carolina, United States
USO - Oncology Hematology Care
🇺🇸Cincinnati, Ohio, United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T
🇺🇸Columbus, Ohio, United States
USO - Oncology Associates of Oregon
🇺🇸Eugene, Oregon, United States
Asante Rogue Regional Medical Center
🇺🇸Medford, Oregon, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Providence St. Vincent Medical Center
🇺🇸Portland, Oregon, United States
Kaiser Permanente Interstate Medical Office Central
🇺🇸Portland, Oregon, United States
USO - Alliance Cancer Specialists, PC
🇺🇸Horsham, Pennsylvania, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office
🇺🇸Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
Lifespan Cancer Institute
🇺🇸Providence, Rhode Island, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Prisma Health Cancer Institute
🇺🇸Greenville, South Carolina, United States
Lexington Medical Center
🇺🇸West Columbia, South Carolina, United States
Tennessee Oncology Chattanooga
🇺🇸Chattanooga, Tennessee, United States
University of Tennessee Medical Center
🇺🇸Knoxville, Tennessee, United States
Baptist Memorial Hospital-Memphis
🇺🇸Memphis, Tennessee, United States
Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
USO - US Oncology Research Network
🇺🇸Nashville, Tennessee, United States
USO - Texas Oncology
🇺🇸Webster, Texas, United States
William Beaumont Army Medical Center
🇺🇸Fort Bliss, Texas, United States
Brooke Army Medical Center
🇺🇸Fort Sam Houston, Texas, United States
Houston Methodist Hospital
🇺🇸Houston, Texas, United States
University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Baylor Scott & White Medical Center - Temple
🇺🇸Temple, Texas, United States
The University of Vermont Medical Center Inc.
🇺🇸Burlington, Vermont, United States
University of Virginia Health System
🇺🇸Charlottesville, Virginia, United States
USO - Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
VCU Health Adult Outpatient Pavillion
🇺🇸Richmond, Virginia, United States
Kadlec Clinic Hematology and Oncology
🇺🇸Kennewick, Washington, United States
Swedish Medical Center
🇺🇸Seattle, Washington, United States
VA Puget Sound Health Care System
🇺🇸Seattle, Washington, United States
USO - Northwest Cancer Specialists
🇺🇸Vancouver, Washington, United States
SSM Health Dean Medical Group - South Madison Campus Health Research/Circuit Clinical
🇺🇸Madison, Wisconsin, United States
Gosford Hospital
🇦🇺Gosford, New South Wales, Australia
Icon Cancer Centre Wesley
🇦🇺Auchenflower, Queensland, Australia
Sunshine Coast University Hospital
🇦🇺Birtinya, Queensland, Australia
Mackay Base Hospital
🇦🇺Mackay, Queensland, Australia
Gold Coast University Hospital
🇦🇺Southport, Queensland, Australia
The Townsville Hospital
🇦🇺Townsville, Queensland, Australia
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Ballarat Health Services
🇦🇺Ballarat Central, Victoria, Australia
St Vincent's Hospital
🇦🇺Melbourne, Victoria, Australia
Goulburn Valley Health
🇦🇺Shepparton, Victoria, Australia
Sir Charles Gairdner Hospital
🇦🇺Perth, Western Australia, Australia
Ordensklinikum Linz GmbH Elisabethinen
🇦🇹Linz, Oberösterreich, Austria
Landeskrankenhaus Feldkirch
🇦🇹Feldkirch, Vorarlberg, Austria
Klinik Floridsdorf
🇦🇹Wien, Austria
ZNA Middelheim
🇧🇪Antwerp, Antwerpen, Belgium
AZ Sint-Maarten
🇧🇪Mechelen, Antwerpen, Belgium
Clinique Saint Pierre
🇧🇪Ottignies, Brabant Wallon, Belgium
CHIREC - site delta
🇧🇪Auderghem, Bruxelles-Capitale, Région De, Belgium
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne
🇧🇪Yvoir, Namur, Belgium
UZ Gent
🇧🇪Gent, Oost-Vlaanderen, Belgium
UZ Leuven
🇧🇪Leuven, Vlaams-Brabant, Belgium
AZ Sint-Jan Brugge-Oostende AV
🇧🇪Brugge, West-Vlaanderen, Belgium
AZ Groeninge Campus Kennedylaan
🇧🇪Kortrijk, West-Vlaanderen, Belgium
AZ Glorieux Ronse
🇧🇪Ronse, Belgium
Clinica Amo - Rio Vermelho
🇧🇷Salvador, Bahia, Brazil
Centro de Pesquisa Clínica do Instituto do Câncer do Ceará
🇧🇷Fortaleza, Ceará, Brazil
Sirio-Libanes Brasilia - Centro de Oncologia - Asa Sul
🇧🇷Brasilia, Distrito Federal, Brazil
Hospital Brasilia
🇧🇷Lago sul, Distrito Federal, Brazil
CEDOES
🇧🇷Vitória, Espírito Santo, Brazil
Hospital São Domingos
🇧🇷Bequimao, Maranhão, Brazil
Oncocentro de Minas Gerais
🇧🇷Belo Horizonte, Minas Gerais, Brazil
Oncominas
🇧🇷Pouso Alegre, Minas Gerais, Brazil
Hospital Universitário Evangélico Mackenzie
🇧🇷Curitiba, Paraná, Brazil
Hospital de Cancer de Londrina
🇧🇷Londrina, Paraná, Brazil
Liga Norte Riograndense Contra o Câncer
🇧🇷Natal, Rio Grande Do Norte, Brazil
Hospital Tacchini
🇧🇷Bento Gonçalves, Rio Grande Do Sul, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
🇧🇷Ijui, Rio Grande Do Sul, Brazil
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos
🇧🇷Barretos, São Paulo, Brazil
Faculdade de Medicina do ABC
🇧🇷Santo André, São Paulo, Brazil
Hospital Sírio Libanês
🇧🇷Sao Paulo, São Paulo, Brazil
Hospital BP
🇧🇷Sao Paulo, São Paulo, Brazil
Hospital Paulistano
🇧🇷Sao Paulo, São Paulo, Brazil
Instituto D'Or de Pesquisa e Ensino (IDOR)
🇧🇷Sao Paulo, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto
🇧🇷São José do Rio Preto, São Paulo, Brazil
COE Ensino e Pesquisa
🇧🇷São José dos Campos, São Paulo, Brazil
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
🇧🇷Rio de Janeiro, Brazil
Centro de Tratamento de Tumores Botafogo para Oncoclinicas Rio de Janeiro SA
🇧🇷Rio de Janeiro, Brazil
Instituto D'Or Pesquisa e Ensino
🇧🇷Rio de Janeiro, Brazil
Icesp - Instituto Do Câncer Do Estado de São Paulo
🇧🇷São Paulo, Brazil
Hospital Santa Catarina - Paulista
🇧🇷São Paulo, Brazil
Centro Paulista de Oncologia Clínica
🇧🇷São Paulo, Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo
🇧🇷São Paulo, Brazil
Instituto de Assistência Médica ao Servidor Público Estadual - IAMSPE/HSPE-FMO Conhecer Centro de Oncolog -T
🇧🇷São Paulo, Brazil
BC Cancer Abbotsford
🇨🇦Abbotsford, British Columbia, Canada
BC Cancer Vancouver
🇨🇦Vancouver, British Columbia, Canada
CIUSSS- saguenay-Lac-Saint-Jean
🇨🇦Chicoutimi, Quebec, Canada
Wannan Medical College Yijishan Hospital
🇨🇳Wuhu, Anhui, China
Cancer Hospital Chinese Academy of Medical Science
🇨🇳Beijing, Beijing, China
Beijing Cancer hospital
🇨🇳Beijing, Beijing, China
Fujian Cancer Hospital
🇨🇳Fuzhou, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University
🇨🇳Zhanjiang, Guangdong, China
Liuzhou People's Hospital
🇨🇳Liuzhou, Guangxi, China
Hainan General Hospital
🇨🇳Haikou, Hainan, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, Heilongjiang, China
Tongji Hospital Tongji Medical,Science & Technology
🇨🇳Wuhan, Hubei, China
Wuhan Union Hospital
🇨🇳Wuhan, Hubei, China
Renmin Hospital of Wuhan University
🇨🇳Wuhan, Hubei, China
Xiangyang Central Hospital
🇨🇳Xiangyang, Hubei, China
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China
ZhuZhou Central Hospital
🇨🇳Zhuzhou, Hunan, China
The First People's Hospital of Changzhou
🇨🇳Changzhou, Jiangsu, China
Nanjing First Hospital
🇨🇳Nanjing, Jiangsu, China
Nantong Tumor Hospital
🇨🇳Nantong, Jiangsu, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Jilin Cancer Hospital
🇨🇳Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Jinan Central Hospital
🇨🇳Jinan, Shandong, China
Shandong Cancer Hospital
🇨🇳Jinan, Shandong, China
LinYi Cancer Hospital
🇨🇳Linyi, Shandong, China
Shanghai Chest Hospital
🇨🇳Shanghai, Shanghai, China
West China Hospital, Sichuan University
🇨🇳Cheng Du, Sichuan, China
The Third People's Hospital of Chengdu (CDTPH)
🇨🇳Chengdu, Sichuan, China
Sichuan Cancer hospital
🇨🇳Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital of Xinjiang Medical University
🇨🇳Urumchi, Xinjiang, China
Xinjiang Medical University Cancer Hospital - Urumqi
🇨🇳Urumqi, Xinjiang, China
The First Affiliated Hospital, Zhejiang University
🇨🇳Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
🇨🇳Linhai, Zhejiang, China
Hwa Mei Hospital University of Chinese Academy of Sciences
🇨🇳Ningbo, Zhejiang, China
Yichang Central People's Hospital
🇨🇳Yichang, China
Nemocnice AGEL Ostrava - Vitkovice a.s.
🇨🇿Ostrava, Ostrava Město, Czechia
Fakultni nemocnice Bulovka
🇨🇿Prague, Praha 8, Czechia
Roskilde University Hospital
🇩🇰Roskilde, Sjælland, Denmark
Centre Antoine-Lacassagne
🇫🇷Nice, Alpes-Maritimes, France
Nouvel Hôpital Civil (NHC)
🇫🇷Strasbourg, Alsace, France
CHU Bordeaux Haut-Leveque
🇫🇷Pessac, Aquitaine, France
CHU de Toulouse - Hopital Larrey
🇫🇷Toulouse, Haute-Garonne, France
Hôpital Foch
🇫🇷Suresnes, Hauts-de-Seine, France
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou
🇫🇷Rennes, Ille-et-Vilaine, France
Institut de Cancérologie de l'Ouest
🇫🇷Saint Herblain, Loire-Atlantique, France
Hôpital Robert Schuman
🇫🇷Vantoux, Lorraine, France
Institut Jean Godinot
🇫🇷Reims, Marne, France
CHU Lille - Institut Coeur Poumon
🇫🇷Lille Cedex, Nord, France
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer
🇫🇷Toulon, Provence-Alpes-Côte-d'Azur, France
Centre Leon Berard
🇫🇷Lyon Cedex08, Rhône-Alpes, France
Hospices Civils de Lyon - Hopital Louis Pradel
🇫🇷Bron, Rhône, France
Gustave Roussy
🇫🇷Villejuif, Val-de-Marne, France
Sainte Catherine Institut du Cancer Avignon Provence
🇫🇷Avignon, Vaucluse, France
Centre Hospitalier Universitaire de Poitiers
🇫🇷Poitiers, Vienne, France
Institut Curie
🇫🇷Paris, France
Universitaetsklinikum Freiburg
🇩🇪Freiburg, Baden-Württemberg, Germany
Thoraxklinik-Heidelberg gGmbH
🇩🇪Heidelberg, Baden-Württemberg, Germany
Universitaetsklinikum Tuebingen
🇩🇪Tübingen, Baden-Württemberg, Germany
Onkologiezentrum Donauwörth
🇩🇪Donauwörth, Bayern, Germany
Asklepios Fachkliniken München-Gauting
🇩🇪Gauting, Bayern, Germany
Klinikum Nürnberg Nord
🇩🇪Nürnberg, Bayern, Germany
MV-Zentrum für Onkologie und Hämatologie
🇩🇪Cologne, Nordrhein-Westfalen, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus
🇩🇪Münster, Nordrhein-Westfalen, Germany
Krankenhaus Martha-Maria Halle-Dölau
🇩🇪Halle, Sachsen-Anhalt, Germany
Klinikum Chemnitz
🇩🇪Chemnitz, Sachsen, Germany
LungenClinic Grosshansdorf
🇩🇪Grosshansdorf, Schleswig-Holstein, Germany
HELIOS Klinikum Erfurt
🇩🇪Erfurt, Thüringen, Germany
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
Charité Campus Virchow-Klinikum
🇩🇪Berlin, Germany
Helios Klinikum Emil von Behring Berlin-Zehlendorf
🇩🇪Berlin, Germany
Franziskus-Hospital Harderberg
🇩🇪Georgsmarienhütte, Germany
Hämato-Onkologie Hamburg, Prof. Laack und Partner
🇩🇪Hamburg, Germany
Asklepios Klinik Harburg
🇩🇪Hamburg, Germany
University Hospital of Patras
🇬🇷Patras, Achaḯa, Greece
Agios Savvas Regional Cancer Hospital
🇬🇷Athens, Attikí, Greece
Errikos Dunant Hospital Center
🇬🇷Athens, Attikí, Greece
Sotiria Thoracic Diseases Hospital of Athens
🇬🇷Athens, Attikí, Greece
Attikon General University Hospital
🇬🇷Chaidari, Attikí, Greece
University General Hospital of Heraklion
🇬🇷Heraklion, Irakleío, Greece
"Theagenio" Cancer Hospital of Thessaloniki
🇬🇷Thessaloniki, Kentrikí Makedonía, Greece
European Interbalkan Medical Center
🇬🇷Thessaloniki, Thessaloníki, Greece
G. Papanikolaou General Hospital
🇬🇷Thessaloniki, Thessaloníki, Greece
Bacs-Kiskun Megyei Korhaz
🇭🇺Kecskemét, Bács-Kiskun, Hungary
Országos Korányi Pulmonológiai Intézet
🇭🇺Budapest, Pest, Hungary
Farkasgyepui Tudogyogyintezet
🇭🇺Farkasgyepu, Veszprém, Hungary
Országos Onkológiai Intézet
🇭🇺Budapest, Hungary
Budapesti Uzsoki Utcai Kórház
🇭🇺Budapest, Hungary
Mahatma Gandhi Cancer Hospital and Research Institute
🇮🇳Visakhapatnam, Andhra Pradesh, India
Hemato Oncology Clinic
🇮🇳Ahmedabad, Gujarat, India
KLES Dr. Prabhakar Kore Hospital & M.R.C
🇮🇳Belagavi, Karnataka, India
SRV Hospitals
🇮🇳Bengaluru, Karnataka, India
Regional Cancer Centre - Thiruvananthapuram
🇮🇳Thiruvananthapuram, Kerala, India
Krishna Institute of Medical Sciences - Karad
🇮🇳Karad, Maharashtra, India
Kolhapur Cancer Centre Private Limited
🇮🇳Kolhapur, Maharashtra, India
Tata Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
HCG Manavata Cancer Centre
🇮🇳Nashik, Maharashtra, India
Grant Medical Foundation - Ruby Hall Clinic
🇮🇳Pune, Maharashtra, India
Sahyadri Super Speciality Hospital
🇮🇳Pune, Maharashtra, India
Lifepoint Multispeciality Hospital
🇮🇳Pune, Maharashtra, India
All India Institute of Medical Sciences
🇮🇳Bhubaneswar, Odisha, India
Pacific Medical College & Hospital
🇮🇳Udaipur, Rajasthan, India
Ashwin Hospital
🇮🇳Coimbatore, Tamil Nadu, India
Nizam's Institute of Medical Sciences
🇮🇳Hyderabad, Telangana, India
Tata Memorial Centre - Homi Bhabha Cancer Hospital
🇮🇳Varanasi, Uttar Pradesh, India
Jawaharlal Institute Of Postgraduate Medical Education And Research
🇮🇳Puducherry, India
Istituto Nazionale Tumori IRCCS Fondazione Pascale
🇮🇹Napoli, Campania, Italy
Fondazione Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milan, Lombardia, Italy
Instituto Tumori Giovanni Paolo II
🇮🇹Bari, Puglia, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Rome, Roma, Italy
Policlinico "G. Rodolico"
🇮🇹Catania, Sicilia, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
🇮🇹Verona, Veneto, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
🇮🇹Bologna, Italy
Istituto Oncologico Veneto IRCCS
🇮🇹Padova, Italy
Ospedale di Circolo e Fondazione Macchi Varese
🇮🇹Varese, Italy
Aichi Cancer Center Hospital
🇯🇵Nagoya, Aichi, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center
🇯🇵Matsuyama, Ehime, Japan
National Hospital Organization Asahikawa Medical Center
🇯🇵Asahikawa, Hokkaido, Japan
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Himeji Medical Center
🇯🇵Himeji, Hyogo, Japan
Kobe City Medical Center General Hospital
🇯🇵Kobe, Hyogo, Japan
Ibaraki Prefectural Central Hospital
🇯🇵Kasama, Ibaraki, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Ishikawa, Japan
Kanagawa Cardiovascular and Respiratory Center
🇯🇵Yokohama, Kanagawa, Japan
Kanagawa cancer center
🇯🇵Yokohama, Kanagawa, Japan
Miyagi Cancer Center
🇯🇵Natori, Miyagi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata-shi, Niigata, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Osaka, Japan
Kindai University Hospital- Osakasayama Campus
🇯🇵Osakasayama, Osaka, Japan
National Hospital Organization Kinki-chuo Chest Medical Center
🇯🇵Sakai, Osaka, Japan
Saitama Medical University International Medical Center
🇯🇵Hidaka, Saitama, Japan
Shizuoka Cancer Center
🇯🇵Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
Tochigi Cancer Center
🇯🇵Utsunomiya, Tochigi, Japan
Tokyo Metropolitan Komagome Hospital
🇯🇵Bunkyo ku, Tokyo, Japan
Juntendo University Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
Japanese Foundation for Cancer Research
🇯🇵Koto, Tokyo, Japan
Tottori University Hospital
🇯🇵Yonago, Tottori, Japan
National Hospital Organization Yamaguchi Ube Medical Center
🇯🇵Ube, Yamaguchi, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
University Hospital,Kyoto Prefectural University of Medicine
🇯🇵Kyoto, Japan
Nagasaki University Hospital
🇯🇵Nagasaki, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Chungcheongbuk-do [Chungbuk], Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Hwasun, Jeonranamdo, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Kyǒnggi-do, Korea, Republic of
The Catholic University Of Korea St. Vincent's Hospital
🇰🇷Suwon-si, Kyǒnggi-do, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan, Kyǒngsangnam-do, Korea, Republic of
Gangnam Severance Hospital, Yonsei University Health System
🇰🇷Gangnam-gu, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Hanyang University Seoul Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
The Catholic University of Korea, Yeouido St. Mary's Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Keimyung University Dongsan Hospital
🇰🇷Daegu, Taegu-Kwangyǒkshi, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Deagu, Taegu-Kwangyǒkshi, Korea, Republic of
Health Pharma Professional Research S.A. de C.V:
🇲🇽Ciudad de México, Distrito Federal, Mexico
Centro Onco-Hematológico Roma (COHR)
🇲🇽Mexico City, Distrito Federal, Mexico
Higiea Oncologia
🇲🇽Mexico City, Distrito Federal, Mexico
Preparaciones Oncológicas S.C.
🇲🇽León, Guanajuato, Mexico
CIO - Centro de Inmuno-Oncología de Occidente
🇲🇽Guadalajara, Jalisco, Mexico
PanAmerican Clinical Research - Guadalajara
🇲🇽Guadalajara, Jalisco, Mexico
Actualidad Basada en la Investigación del Cáncer
🇲🇽Guadalajara, Jalisco, Mexico
Renati Innovation
🇲🇽Guadalajara, Jalisco, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
🇲🇽Monterrey, Nuevo León, Mexico
Avix Investigación Clinica, S.C.
🇲🇽Monterrey, Nuevo León, Mexico
Oncare - Unidad Valle
🇲🇽San Pedro Garza García, Nuevo León, Mexico
Health Pharma Querétaro
🇲🇽Juriquilla, Querétaro, Mexico
Centro de Investigacion Clinica de Oaxaca
🇲🇽Oaxaca, Mexico
Clinica Integral Internacional de Oncología
🇲🇽Puebla, Mexico
Arké SMO S.A de C.V
🇲🇽Veracruz, Mexico
Medische Centrum Leeuwarden
🇳🇱Leeuwarden, Fryslân, Netherlands
Ziekenhuis St. Jansdal
🇳🇱Harderwijk, Gelderland, Netherlands
Jeroen Bosch Hospital
🇳🇱Den Bosch, Noord-Brabant, Netherlands
ETZ Elisabeth
🇳🇱Tilburg, Noord-Brabant, Netherlands
Tergooiziekenhuizen, locatie Hilversum
🇳🇱Hilversum, Noord-Holland, Netherlands
Medisch Spectrum Twente
🇳🇱Enschede, Overijssel, Netherlands
Leids Universitair Medisch Centrum
🇳🇱Leiden, Zuid-Holland, Netherlands
Erasmus Medisch Centrum
🇳🇱Rotterdam, Zuid-Holland, Netherlands
St. Antonius Ziekenhuis, locatie Utrecht
🇳🇱Utrecht, Netherlands
Akershus Universitetssykehus
🇳🇴Lørenskog, Akershus, Norway
Drammen Sykehus, Vestre Viken HF
🇳🇴Drammen, Buskerud, Norway
Haukeland Universitetssjukehus
🇳🇴Bergen, Hordaland, Norway
Sykehuset Innlandet HF Gjøvik
🇳🇴Gjøvik, Oppland, Norway
Stavanger Universitetssykehus
🇳🇴Stavanger, Rogaland, Norway
St. Olavs Hospital
🇳🇴Trondheim, Sør-Trøndelag, Norway
Oslo universitetssykehus, Radiumhospitalet
🇳🇴Oslo, Norway
MICS Centrum Medyczne Torun
🇵🇱Torun, Kujawsko-pomorskie, Poland
One Day Med
🇵🇱Szczecin, Zachodniopomorskie, Poland
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej
🇵🇱Kielce, Świętokrzyskie, Poland
Champalimaud Foundation
🇵🇹Lisbon, Lisboa, Portugal
Hospital Pulido Valente
🇵🇹Lisbon, Lisboa, Portugal
Centro Hospitalar E Universitário De Coimbra
🇵🇹Coimbra, Portugal
Hospital da Luz Lisboa
🇵🇹Lisboa, Portugal
Centro Hospitalar do Porto - Hospital de Santo António
🇵🇹Porto, Portugal
Hospital CUF Porto
🇵🇹Porto, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
🇵🇹Porto, Portugal
Lotus-Med
🇷🇴Bucharest, București, Romania
SC Memorial Healthcare International SRL
🇷🇴Bucharest, București, Romania
Ovidius Clinical Hospital OCH
🇷🇴Ovidiu, Constanța, Romania
Centrul de Oncologie "Sfântul Nectarie"
🇷🇴Craiova, Dolj, Romania
S C Oncocenter Oncologie Clinica S R L
🇷🇴Timișoara, Timiș, Romania
Cabinet Medical Oncomed
🇷🇴Timișoara, Timiș, Romania
Gral Medical Diagnostic Center
🇷🇴București, Romania
Institutul Oncologic
🇷🇴Cluj, Romania
CHUAC-Hospital Teresa Herrera
🇪🇸A Coruña, A Coruña [La Coruña], Spain
CHUS - Hospital Clinico Universitario
🇪🇸Santiago de Compostela, A Coruña [La Coruña], Spain
Hospital Universitari Son Espases
🇪🇸Palma, Balears [Baleares], Spain
Parc de Salut Mar - Hospital del Mar
🇪🇸Barcelona, Barcelona [Barcelona], Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Barcelona [Barcelona], Spain
Instituto Catalan de Oncologia - Hospital Duran i Reynals
🇪🇸Hospitalet, Barcelona [Barcelona], Spain
Complejo Asistencial Universitario de León - Hospital de León
🇪🇸León, Castilla Y León, Spain
Hospital Universitari Dexeus
🇪🇸Barcelona, Catalunya [Cataluña], Spain
Hospital Jerez de la Frontera
🇪🇸Jerez de la Frontera, Cádiz, Spain
Hospital Insular de Gran Canaria
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Madrid, Comunidad De, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Madrid, Comunidad De, Spain
Hospital Universitario Quironsalud Madrid
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Complejo Hospitalario de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Clinico de Valencia
🇪🇸Valencia, Valenciana, Comunitat, Spain
Hospital Infanta Cristina
🇪🇸Badajoz, Spain
H.R.U Málaga - Hospital General
🇪🇸Málaga, Spain
Hospital Universitario Virgen Del Rocio
🇪🇸Sevilla, Spain
Hospital Clínico Universitario Lozano Blesa
🇪🇸Zaragoza, Spain
Mälarsjukhuset
🇸🇪Eskilstuna, Södermanlands Län [se-04], Sweden
Västmanlands Sjukhus Västerås
🇸🇪Västerås, Västmanlands Län [se-19], Sweden
CHUV (centre hospitalier universitaire vaudois)
🇨🇭Lausanne, Vaud, Switzerland
Kantonsspital Winterthur
🇨🇭Winterthur, Switzerland
UniversitätsSpital Zürich
🇨🇭Zürich, Switzerland
Changhua Christian Hospital
🇨🇳Changhua County, Changhua, Taiwan
National Taiwan University Hospital - Hsinchu branch
🇨🇳Zhu Bei City, Hsinchu, Taiwan
Hualien Tzu Chi Medical Center
🇨🇳Hualien City, Hualien, Taiwan
Chang Gung Memorial Hospital at Kaohsiung
🇨🇳Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
New Taipei Municipal TuCheng Hospital
🇨🇳New Taipei City, New Taipei, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung City, Taichung, Taiwan
Chi Mei Medical Center
🇨🇳Tainan City, Tainan, Taiwan
Chi Mei Hospital - Liouying Branch
🇨🇳Tainan City, Tainan, Taiwan
National Taiwan University Cancer Center (NTUCC)
🇨🇳Taipei City, Taipei, Taiwan
National Taiwan University Hospital Yun-Lin Branch Dou-Liou Region
🇨🇳Douliu City, Yunlin, Taiwan
Buddhist Dalin Tzu Chi General Hospital
🇨🇳Chiayi, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch
🇨🇳Taoyuan, Taiwan
Adana Medical Park Seyhan Hastanesi
🇹🇷Adana, Turkey
Adana City Hospital
🇹🇷Adana, Turkey
Ankara Etlik City Hospital
🇹🇷Ankara, Turkey
Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital
🇹🇷Ankara, Turkey
Ankara Bilkent Şehir Hastanesi
🇹🇷Ankara, Turkey
Akdeniz Universitesi Hastanesi
🇹🇷Antalya, Turkey
Memorial Antalya Hospital
🇹🇷Antalya, Turkey
Uludag Universitesi
🇹🇷Bursa, Turkey
Dicle Üniversitesi
🇹🇷Diyarbakir, Turkey
Bezmialem Vakf Üniversitesi
🇹🇷Istanbul, Turkey
İ.A.Ü VM Medical Park Florya Hastanesi
🇹🇷Istanbul, Turkey
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
🇹🇷Istanbul, Turkey
Ege Universitesi Hastanesi
🇹🇷Izmir, Turkey
zmir Katip Çelebi Üniversitesi Atatürk Eitim Ve Aratrma Hastanesi
🇹🇷Izmir, Turkey
Kocaeli Üniversitesi
🇹🇷Kocaeli, Turkey
Ondokuz Mayıs Universitesi
🇹🇷Samsun, Turkey
Aberdeen Royal Infirmary
🇬🇧Aberdeen, Aberdeen City, United Kingdom
Ninewells Hospital and Medical School
🇬🇧Dundee, Dundee City, United Kingdom
Huddersfield Royal Infirmary
🇬🇧Huddersfield, England, United Kingdom
Weston Park Hospital
🇬🇧Sheffield, England, United Kingdom
Cheltenham General Hospital
🇬🇧Cheltenham, Gloucestershire, United Kingdom
Mount Vernon Hospital
🇬🇧Northwood, Hillingdon, United Kingdom
St James's University Hospital
🇬🇧Leeds, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
New Cross Hospital
🇬🇧Wolverhampton, United Kingdom